Namaxir (Methotrexate)

Methotrexate, the active ingredient in Namaxir, is an antimetabolite (folate antagonist) presented as a sterile injectable for epidural, intra‑articular and intramuscular use. It is employed to manage rheumatoid arthritis, severe psoriasis, selected malignancies such as leukemia and lymphoma, and ectopic pregnancy in appropriate patients.

GNH USA supplies Namaxir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from regulatory compliance and dedicated technical support.

Methotrexate is a folate antagonist used in several disease categories, primarily autoimmune and oncologic conditions.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and plaque formation. - Certain cancers (e.g., leukemia, lymphoma): interferes with rapid cell proliferation to achieve disease control. - Ectopic pregnancy: halts trophoblastic growth to allow non‑surgical resolution.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Mild oral ulceration. - Transient elevation of liver enzymes. - Low white‑blood‑cell count. - Hair thinning or loss.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening bone‑marrow suppression. - Renal failure due to crystal nephropathy. - Severe cutaneous reactions such as Stevens‑Johnson syndrome. - Teratogenic effects leading to fetal malformations.

Methotrexate requires careful monitoring and specific safety measures before and during therapy.

- Pregnancy: contraindicated (Category X); avoid use in pregnant or planning‑to‑conceive patients. - Renal function: assess creatinine clearance; adjust or discontinue if impairment is significant. - Hepatic function: obtain baseline liver enzymes and monitor regularly for toxicity. - Hematologic monitoring: perform complete blood counts before each dose and periodically thereafter. - Infection risk: postpone treatment in the presence of active infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate serum levels and risk of renal toxicity. - Penicillins (e.g., ampicillin): reduce renal clearance, raising methotrexate exposure. - Live vaccines: heightened risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Sulfonamides and trimethoprim: additive bone‑marrow suppression. - Proton pump inhibitors: may affect renal elimination. - Alcohol: potentiates hepatotoxicity. - Azathioprine or other immunosuppressants: increase risk of cytopenias.